Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences ( (TLSA) ) has shared an update.
On July 21, 2025, Tiziana Life Sciences announced significant immunologic findings from the treatment of a moderate Alzheimer’s Disease patient using intranasal foralumab. The study revealed profound immune modulatory effects, including changes in immune cell profiles and a reduction in brain inflammation. An unexpected increase in phagocytosis markers suggests potential for clearing amyloid plaques, opening new treatment avenues for Alzheimer’s. The results, which showed no side effects, mark a milestone in Alzheimer’s therapy development and highlight Tiziana’s commitment to advancing treatments for neurodegenerative disorders.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody currently in clinical development, with potential applications in treating neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 317,855
Technical Sentiment Signal: Buy
Current Market Cap: $172.8M
For an in-depth examination of TLSA stock, go to TipRanks’ Overview page.